Marinomed Biotech AG logo

MARI - Marinomed Biotech AG News Story

€123.5 -0.5  -0.4%

Last Trade - 3:04pm

Sector
Healthcare
Size
Small Cap
Market Cap £157.1m
Enterprise Value £160.2m
Revenue £6.98m
Position in Universe 661st / 1053

BRIEF-Marinomed Positive Clinical Data For Carragelose Lozenges Against Respiratory Viruses

Wed 24th February, 2021 6:47am
Feb 24 (Reuters) - MARINOMED BIOTECH AG  MARI.VI :
    * POSITIVE CLINICAL DATA FOR CARRAGELOSE LOZENGES AGAINST
RESPIRATORY VIRUSES INCLUDING SARS-COV-2
    * NEW DATA SUPPORT THAT CARRAGELOSE LOZENGES MAY PREVENT
VIRAL
INFECTIONS AND REDUCE VIRAL TRANSMISSION, INCLUDING SARS-COV-2
    * SALIVA AFTER CONSUMPTION OF ONLY ONE CARRAGELOSE LOZENGE
IS
SUFFICIENT TO INACTIVATE MULTIPLE RESPIRATORY VIRUSES, INCLUDING
SARS-COV-2
    * CARRAGELOSE IN SALIVA GREATLY EXCEEDED CONCENTRATIONS
REQUIRED
FOR VIRUS NEUTRALIZATION
    * INDEPENDENT RESULTS FROM ARGENTINA CONFIRM CLINICAL
EFFICACY OF
CARRAGELOSE NASAL SPRAY IN COVID-19 PREVENTION

Source text for Eikon:  ID:nPexfNvP0a 
Further company coverage:  MARI.VI 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.